CSL Akcija

CSL ROE

Delisted·19. јун 2026.

Vrijednost ROE (Return on Equity) od CSL (CSL.AX) na dan 7. авг 2026. je 15,53 %. Prethodne godine, ROE (Return on Equity) je bio 15,22 % — promjena od 2,04% (viši).

ROE

15,53 %

YoY

2,04%

Zadnja ažuriranja:

U godini 2026 rentabilnost sopstvenog kapitala (ROE) kompanije CSL iznosila je 15,53 %, što je porast od 2,04% u poređenju sa 15,22 % ROE prethodne godine.

Access this data via the Eulerpool API

CSL Анализа акција

Šta radi CSL? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL je jedna od najpopularnijih kompanija na Eulerpool.

ROE у детаљу

Razjašnjenje povrata na sopstveni kapital (ROE) kompanije CSL

Povraćaj na sopstveni kapital (ROE) kompanije CSL je osnovni pokazatelj koji ocenjuje profitabilnost kompanije u odnosu na sopstveni kapital. ROE, izračunat deljenjem neto dobiti sa sopstvenim kapitalom akcionara, ilustruje efikasnost kompanije u ostvarivanju profita iz investicija akcionara. Viši ROE označava povećanu efikasnost i profitabilnost.

Poređenje iz godine u godinu

Analiza ROE kompanije CSL iz godine u godinu pomaže u praćenju trendova profitabilnosti i finansijskih performansi. Rastući ROE ukazuje na povećanu profitabilnost i stvaranje vrednosti za akcionare, dok opadajući ROE može ukazivati na probleme u stvaranju dobiti ili upravljanju sopstvenim kapitalom.

Uticaj na investicije

ROE kompanije CSL je ključan za investitore koji ocenjuju profitabilnost, efikasnost i privlačnost kompanije kao investicije. Robusni ROE ukazuje na sposobnost kompanije da pretvori investicije sopstvenog kapitala u profit, čime povećava svoju privlačnost potencijalnim i sadašnjim investitorima.

Interpretacija fluktuacija ROE

Promene u ROE kompanije CSL mogu proizaći iz fluktuacija neto dobiti, sopstvenog kapitala ili oboje. Ove fluktuacije se analiziraju sa ciljem procene efikasnosti menadžmenta, finansijskih strategija, kao i povezanih rizika i mogućnosti, te pomažu investitorima u donošenju obrazloženih odluka.

Često postavljena pitanja o akciji CSL

ROE (Return on Equity) kompanije CSL iznosi 15,53 % u 2026. godini.

ROE (Return on Equity) od CSL se promijenio sa 15,22 % na 15,53 %, što predstavlja promjenu od 2,04%. Vrijednost je viši nego prethodne godine.

Na Eulerpool-u možete pronaći potpuni historijski razvoj ROE (Return on Equity) CSL od 2006. — sa godišnjim vrijednostima, grafikonima i detaljnom analizom.

Dobar varira u zavisnosti od industrije i faze razvoja preduzeća. Na Eulopoolu, možete porediti ROE (Return on Equity)'s CSL sa sličnim preduzećima u sektoru i prosekom industrije da biste proverili da li je atraktivan.

Da biste proverili ROE (Return on Equity)'s, bitno je da ga uporedite sa konkurentima u istoj industriji i sektoru. Na Eulopoolu, možete pronaći direktna upoređivanja industrije za ROE (Return on Equity).

Access this data via the Eulerpool API

Профитабилност — CSL

Sve ključne metrike — CSL

Раст